Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,863 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Parkinson Disease Clear all
Active, not recruiting Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
35 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Phase 2 Interventional

DNS-7801 vs. Placebo in Parkinson's Disease

NCT03306329
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DNS-7801 (low-dose), DNS-7801 (high dose), Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
30 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
9
States / cities
Long Beach, California • Pasadena, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Not applicable Interventional

Piano Training, Caregivers, and Parkinson's Disease

NCT03922672
View directory record Official record
Conditions
Depression, Mood, Burden, Dependency
Interventions
Group piano training
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 1 Interventional

Measuring Parkinson's Disease Progression

NCT03205956
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa
Drug
Lead sponsor
Kevin J. Black, MD
Other
Eligibility
40 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets

NCT02812394
View directory record Official record
Conditions
Parkinson Disease
Interventions
CVT-301 (Dose Level 1), CVT-301 (Dose Level 2), Sinemet®
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

NCT05508867
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
favezelimab/pembrolizumab, bendamustine, gemcitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 3 Interventional

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

NCT00139867
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PARCOPA
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Timeline
2004
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

Valerian to Improve Sleep in Patients With Parkinson's Disease

NCT00070928
View directory record Official record
Conditions
Insomnia, Parkinson's Disease
Interventions
valerian
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
30 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 26, 2006 · Synced Oct 7, 2026, 9:47 PM EDT
Completed No phase listed Observational

Parkinson's Disease in African American and Caucasian Patients

NCT03279445
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
15 Years to 100 Years
Enrollment
2,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

NCT02274766
View directory record Official record
Conditions
Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
Interventions
ADS-5102, Placebo
Drug · Other
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
21
States / cities
Fountain Valley, California • Sunnyvale, California • Boca Raton, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 7, 2026, 9:47 PM EDT
Recruiting No phase listed Observational

Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder

NCT07217054
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder), Parkinson, Parkinson s Disease, Parkinson Disease
Interventions
Not listed
Lead sponsor
CND Life Sciences
Other
Eligibility
40 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Branford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Not applicable Interventional

The Effect of Psyllium and Wheat Bran on Body Weight in People With Parkinson's Disease and Constipation Symptoms

NCT04829760
View directory record Official record
Conditions
Parkinson Disease
Interventions
Psyllium, Coarse wheat bran, Maltodextrin
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
40 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 7, 2026, 9:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Autonomic Failure Patients for RNA Blood Sampling

NCT00742586
View directory record Official record
Conditions
Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Plus Syndromes
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
50 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

NCT03924869
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Placebo
Radiation · Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 7, 2026, 9:47 PM EDT
Recruiting Phase 1 Interventional

Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease

NCT07557706
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
transcutaneous auricular vagus nerve stimulation
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Not listed No phase listed Observational

Measures of Mitochondria Dysfunction in PD

NCT04300608
View directory record Official record
Conditions
Parkinson Disease, Mitochondrial
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
65 Years to 85 Years
Enrollment
30 participants
Timeline
2020 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Longitudinal Analysis of Gait Variability to Predict Falls in Parkinson's Disease

NCT04339543
View directory record Official record
Conditions
Parkinson Disease, Healthy Aging
Interventions
Cognitive dual-task walking
Other
Lead sponsor
University of Nebraska
Other
Eligibility
60 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 7, 2026, 9:47 PM EDT
Completed No phase listed Observational

Studies of Frontal Lobe Brain Functioning in Schizophrenia

NCT00001258
View directory record Official record
Conditions
Healthy Subjects, Schizophrenia, Parkinson Disease
Interventions
Oxygen-15 Water
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 90 Years
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed No phase listed Observational

Imaging Biomarkers in Parkinson s Disease

NCT01496599
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 100 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Not applicable Interventional

Periodization and Parkinson's Disease

NCT07141849
View directory record Official record
Conditions
Activity, Motor
Interventions
Power Resistance Training, Periodized Resistance Training
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
50 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 7, 2026, 9:47 PM EDT
Terminated Phase 3 Interventional Results available

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

NCT00740714
View directory record Official record
Conditions
Parkinson Disease
Interventions
Coenzyme Q10 with vitamin E, placebo with vitamin E
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 7, 2026, 9:47 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease

NCT00026598
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 7, 2026, 9:47 PM EDT
Completed Not applicable Interventional

Low Vision Occupational Therapy in Parkinson's Disease

NCT04127838
View directory record Official record
Conditions
Parkinson Disease
Interventions
Low Vision Occupational Therapy
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 7, 2026, 9:47 PM EDT